NASDAQ:PHVS Pharvaris Q2 2025 Earnings Report $31.61 -0.30 (-0.95%) As of 11:53 AM Eastern This is a fair market value price provided by Massive. Learn more. ProfileEarnings HistoryForecast Pharvaris EPS ResultsActual EPS-$0.94Consensus EPS -$0.87Beat/MissMissed by -$0.07One Year Ago EPSN/APharvaris Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/APharvaris Announcement DetailsQuarterQ2 2025Date8/12/2025TimeBefore Market OpensConference Call DateMonday, August 11, 2025Conference Call Time6:00PM ETUpcoming EarningsPharvaris' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled on Thursday, November 12, 2026 at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K) Pharvaris Earnings HeadlinesPharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from BrokeragesSeptember 29 at 4:29 AM | americanbankingnews.comPharvaris (NASDAQ:PHVS) Stock: Insider Johannes Gerardus Chri Schikan Sells 800 SharesSeptember 26 at 6:26 AM | americanbankingnews.comALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings. Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds. If any of these are in your portfolio, now is the time to review your positions.September 29 at 1:00 AM | Weiss Ratings (Ad)Pharvaris (NASDAQ:PHVS) Director Viviane Monges Sells 11,969 Shares of StockSeptember 26 at 5:39 AM | americanbankingnews.comPharvaris (NASDAQ:PHVS) CFO David Nassif Sells 6,000 SharesSeptember 24, 2026 | americanbankingnews.comJohannes Gerardus Chri Schikan Sells 200,000 Shares of Pharvaris (NASDAQ:PHVS) StockSeptember 23, 2026 | americanbankingnews.comSee More Pharvaris Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Pharvaris? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pharvaris and other key companies, straight to your email. Email Address About PharvarisPharvaris (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group. Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks. The program is designed to provide patients with an oral alternative to currently available injectable or infused therapies. The company has conducted clinical development activities in the United States, Europe and other international markets. Pharvaris’ leadership team includes Chief Executive Officer Berndt Modig, who has experience in the biotechnology and pharmaceutical industries. Deucrictibant remains an investigational product, and Pharvaris’ development programs are subject to the review and approval of regulatory authorities.View Pharvaris ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Bernstein Downgrades 3 Cybersecurity Stocks: How Concerned Should Investors Be?Brewing Trouble? Starbucks Spills the Beans on 250 Store ClosuresMarketBeat Week in Review – 09/21 - 09/25Analyst Rating Boosts May Signal More Upside for These 3 Stocks3 Stocks Under the Microscope After Large Insider Sales3 Healthcare Stocks Showing Why the Sector Still Has Momentum2 Cybersecurity Stocks Breaking Out as AI Continues to Be a Tailwind Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
